|
Gene: GK |
Gene summary for GK |
Gene summary. |
Gene information | Species | Human | Gene symbol | GK | Gene ID | 2710 |
Gene name | glycerol kinase | |
Gene Alias | GK1 | |
Cytomap | Xp21.2 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | B4DH54 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2710 | GK | LZE20T | Human | Esophagus | ESCC | 2.64e-04 | 3.81e-01 | 0.0662 |
2710 | GK | LZE24T | Human | Esophagus | ESCC | 5.03e-06 | 1.70e-01 | 0.0596 |
2710 | GK | LZE21T | Human | Esophagus | ESCC | 1.01e-07 | 6.53e-01 | 0.0655 |
2710 | GK | LZE6T | Human | Esophagus | ESCC | 4.44e-08 | 5.59e-01 | 0.0845 |
2710 | GK | P1T-E | Human | Esophagus | ESCC | 2.39e-12 | 1.35e+00 | 0.0875 |
2710 | GK | P2T-E | Human | Esophagus | ESCC | 1.19e-09 | 2.12e-01 | 0.1177 |
2710 | GK | P8T-E | Human | Esophagus | ESCC | 6.50e-05 | 1.89e-01 | 0.0889 |
2710 | GK | P11T-E | Human | Esophagus | ESCC | 5.83e-07 | 2.10e-01 | 0.1426 |
2710 | GK | P12T-E | Human | Esophagus | ESCC | 4.51e-04 | 1.21e-01 | 0.1122 |
2710 | GK | P16T-E | Human | Esophagus | ESCC | 4.44e-10 | 2.05e-01 | 0.1153 |
2710 | GK | P21T-E | Human | Esophagus | ESCC | 1.34e-06 | 2.57e-01 | 0.1617 |
2710 | GK | P23T-E | Human | Esophagus | ESCC | 3.73e-22 | 1.20e+00 | 0.108 |
2710 | GK | P26T-E | Human | Esophagus | ESCC | 2.11e-09 | 2.23e-01 | 0.1276 |
2710 | GK | P27T-E | Human | Esophagus | ESCC | 3.44e-07 | 1.65e-01 | 0.1055 |
2710 | GK | P28T-E | Human | Esophagus | ESCC | 2.08e-03 | 2.04e-01 | 0.1149 |
2710 | GK | P37T-E | Human | Esophagus | ESCC | 1.09e-08 | 2.47e-01 | 0.1371 |
2710 | GK | P39T-E | Human | Esophagus | ESCC | 5.31e-08 | 2.55e-01 | 0.0894 |
2710 | GK | P47T-E | Human | Esophagus | ESCC | 2.16e-06 | 1.26e-01 | 0.1067 |
2710 | GK | P48T-E | Human | Esophagus | ESCC | 5.79e-06 | 1.28e-01 | 0.0959 |
2710 | GK | P52T-E | Human | Esophagus | ESCC | 4.03e-19 | 5.76e-01 | 0.1555 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00457654 | Prostate | BPH | regulation of angiogenesis | 76/3107 | 342/18723 | 3.90e-03 | 1.95e-02 | 76 |
GO:0007611 | Prostate | BPH | learning or memory | 59/3107 | 255/18723 | 4.12e-03 | 2.04e-02 | 59 |
GO:19050502 | Prostate | BPH | positive regulation of metallopeptidase activity | 6/3107 | 11/18723 | 4.49e-03 | 2.19e-02 | 6 |
GO:19050482 | Prostate | BPH | regulation of metallopeptidase activity | 10/3107 | 25/18723 | 4.57e-03 | 2.19e-02 | 10 |
GO:00305205 | Prostate | BPH | intracellular estrogen receptor signaling pathway | 17/3107 | 54/18723 | 5.09e-03 | 2.40e-02 | 17 |
GO:19001023 | Prostate | BPH | negative regulation of endoplasmic reticulum unfolded protein response | 7/3107 | 15/18723 | 6.42e-03 | 2.91e-02 | 7 |
GO:19001018 | Prostate | BPH | regulation of endoplasmic reticulum unfolded protein response | 11/3107 | 30/18723 | 6.48e-03 | 2.92e-02 | 11 |
GO:0044275 | Prostate | BPH | cellular carbohydrate catabolic process | 13/3107 | 40/18723 | 1.01e-02 | 4.25e-02 | 13 |
GO:006024910 | Prostate | BPH | anatomical structure homeostasis | 68/3107 | 314/18723 | 1.10e-02 | 4.53e-02 | 68 |
GO:19028081 | Prostate | BPH | positive regulation of cell cycle G1/S phase transition | 17/3107 | 58/18723 | 1.11e-02 | 4.54e-02 | 17 |
GO:004603419 | Prostate | Tumor | ATP metabolic process | 122/3246 | 277/18723 | 1.71e-25 | 5.33e-22 | 122 |
GO:004217619 | Prostate | Tumor | regulation of protein catabolic process | 142/3246 | 391/18723 | 9.32e-20 | 5.79e-17 | 142 |
GO:000609117 | Prostate | Tumor | generation of precursor metabolites and energy | 166/3246 | 490/18723 | 2.38e-19 | 1.23e-16 | 166 |
GO:003164719 | Prostate | Tumor | regulation of protein stability | 112/3246 | 298/18723 | 4.18e-17 | 1.18e-14 | 112 |
GO:001049819 | Prostate | Tumor | proteasomal protein catabolic process | 158/3246 | 490/18723 | 3.05e-16 | 6.76e-14 | 158 |
GO:000698619 | Prostate | Tumor | response to unfolded protein | 65/3246 | 137/18723 | 3.56e-16 | 7.50e-14 | 65 |
GO:003497619 | Prostate | Tumor | response to endoplasmic reticulum stress | 97/3246 | 256/18723 | 2.92e-15 | 4.78e-13 | 97 |
GO:004854519 | Prostate | Tumor | response to steroid hormone | 118/3246 | 339/18723 | 4.46e-15 | 6.94e-13 | 118 |
GO:000989619 | Prostate | Tumor | positive regulation of catabolic process | 155/3246 | 492/18723 | 5.62e-15 | 8.52e-13 | 155 |
GO:003596619 | Prostate | Tumor | response to topologically incorrect protein | 69/3246 | 159/18723 | 1.28e-14 | 1.81e-12 | 69 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa033206 | Liver | NAFLD | PPAR signaling pathway | 25/1043 | 75/8465 | 1.61e-06 | 6.62e-05 | 5.33e-05 | 25 |
hsa0332011 | Liver | NAFLD | PPAR signaling pathway | 25/1043 | 75/8465 | 1.61e-06 | 6.62e-05 | 5.33e-05 | 25 |
hsa0332021 | Liver | Cirrhotic | PPAR signaling pathway | 32/2530 | 75/8465 | 1.24e-02 | 3.92e-02 | 2.42e-02 | 32 |
hsa0332031 | Liver | Cirrhotic | PPAR signaling pathway | 32/2530 | 75/8465 | 1.24e-02 | 3.92e-02 | 2.42e-02 | 32 |
hsa033204 | Liver | HCC | PPAR signaling pathway | 48/4020 | 75/8465 | 2.83e-03 | 9.37e-03 | 5.21e-03 | 48 |
hsa005615 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
hsa033205 | Liver | HCC | PPAR signaling pathway | 48/4020 | 75/8465 | 2.83e-03 | 9.37e-03 | 5.21e-03 | 48 |
hsa0056112 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
hsa03320 | Stomach | GC | PPAR signaling pathway | 18/708 | 75/8465 | 3.26e-05 | 4.01e-04 | 2.82e-04 | 18 |
hsa005614 | Stomach | GC | Glycerolipid metabolism | 12/708 | 63/8465 | 5.36e-03 | 3.01e-02 | 2.12e-02 | 12 |
hsa033201 | Stomach | GC | PPAR signaling pathway | 18/708 | 75/8465 | 3.26e-05 | 4.01e-04 | 2.82e-04 | 18 |
hsa0056111 | Stomach | GC | Glycerolipid metabolism | 12/708 | 63/8465 | 5.36e-03 | 3.01e-02 | 2.12e-02 | 12 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GK | SNV | Missense_Mutation | c.65C>T | p.Ser22Leu | p.S22L | P32189 | protein_coding | deleterious(0) | possibly_damaging(0.874) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GK | SNV | Missense_Mutation | rs772353152 | c.1256G>A | p.Arg419Gln | p.R419Q | P32189 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GK | SNV | Missense_Mutation | c.11C>T | p.Ser4Leu | p.S4L | P32189 | protein_coding | tolerated(0.14) | benign(0.012) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GK | SNV | Missense_Mutation | novel | c.1423G>C | p.Val475Leu | p.V475L | P32189 | protein_coding | tolerated(0.07) | benign(0.075) | TCGA-BH-A6R8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GK | SNV | Missense_Mutation | novel | c.772C>G | p.Pro258Ala | p.P258A | P32189 | protein_coding | deleterious(0.02) | probably_damaging(0.981) | TCGA-C5-A8XI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
GK | SNV | Missense_Mutation | rs757334363 | c.1403N>T | p.Ala468Val | p.A468V | P32189 | protein_coding | tolerated(0.06) | benign(0.287) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GK | SNV | Missense_Mutation | c.1654G>T | p.Ala552Ser | p.A552S | P32189 | protein_coding | tolerated(0.19) | probably_damaging(0.997) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GK | SNV | Missense_Mutation | c.1258N>T | p.Asp420Tyr | p.D420Y | P32189 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
GK | SNV | Missense_Mutation | c.1527G>T | p.Trp509Cys | p.W509C | P32189 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6321-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD | |
GK | SNV | Missense_Mutation | c.1651G>A | p.Gly551Arg | p.G551R | P32189 | protein_coding | tolerated(0.35) | probably_damaging(0.99) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |